Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese
Condition: Binge Eating Behaviour
MeSH terms: Overweight; Bulimia; Binge-Eating Disorder
Study type: Interventional
Phase: Phase 4

Summary: 
      Malaysia has increasing challenges in lifestyle related diseases, which is related to eating
      habits and disorders. According to the National Health & Morbidity Survey in 2011; it was
      reported the prevalence of obesity is 15.1% in 2011; or 2.5 million of the population,; an
      increase of 7/9% when compared to the 14% prevalence in 2006. Binge eating is a symptom
      described in various eating disorders. It is an under-diagnosed medical condition closely
      linked to higher body mass index (BMI) or obesity as well as personality psychopathology,
      psychiatric and psychological disturbances. Meta-analysis has demonstrated that extremely
      strict restriction in dietary calorie and fat intake is needed to achieve meaningful weight
      loss. Appetite and satiety are influenced by extremely complex central and gut-related
      hormonal systems which modulate the regulation of food intake Centrally acting hormones
      include Neuropeptide Y (NPY), agouti gene-related peptide, orexin which are
      appetite-stimulating, melanocortins and alpha-melanocortin-stimulating hormone which promote
      satiety.

      Gut-related peptides include ghrelin secreted by the stomach and the duodenum has orexigenic
      (appetite stimulating) effect; leptin secreted by adipose tissue has anorexic (appetite
      inhibiting) effect, cholecystokinin, glucagon-like peptide-1 (GLP-1) secreted by the proximal
      gastrointestinal tract which has slight anorexic effect, and peptide YY (PYY).

      Appetite and obesity have also been commonly related to stress and may influence binge-eating
      episodes. Previous studies have demonstrated that high stress hormone cortisol is associated
      with increased appetite and cravings, with preference for high carbohydrate content, thus
      leading to weight gain.

      In the previous study performed by our group on 738 normal subjects who were staffs of the
      Ministry of Health, Putrajaya, we found a prevalence of 19% binge eating behaviour, 83% of
      whom were either obese or overweight.

      GLP-1 analogue used for the treatment of type 2 diabetes and is also shown to produce and
      maintain weight loss. Liraglutide, which provides a supra physiological amount of GLP-1 may
      cause appetite inhibition thus may benefit in reducing binge eating. The aim of this study is
      to closely observe the extensive profile of neuropeptide Y, ghrelin, leptin and GLP-1,
      influenced by a standard meal in binge eaters in comparison to non-binge eating controls. In
      addition, we aim to determine the association between binging and the respective
      appetite-related hormones and also cortisol. Finally we will also be assessing the efficacy
      of novel hormonal treatment of Liraglutide in reducing binge eating.
    


Intervention name(s): Liraglutide; Diet and Exercise
Intervention type(s): Drug; Behavioral
Intervention description(s): liraglutide; diet and exercise
Other intervention name(s): Victoza
Intervention MeSH terms: Liraglutide
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment